Zohar Keren

Project Manager at Protalix Biotherapeutics - Miami, FL, US

Zohar Keren's Colleagues at Protalix Biotherapeutics
Mirela Jakoel

Chemistry & Raw Material QC Manager

Contact Mirela Jakoel

Zehavit Glants

Quality assurance operations

Contact Zehavit Glants

Dror Kaldes

Calibration & Analytical Equipment Team Leader

Contact Dror Kaldes

Yair Kirshner

Production Senior Director

Contact Yair Kirshner

Kobi Marom

Validation Team Leader

Contact Kobi Marom

Omri Er-El

Engineering manager

Contact Omri Er-El

View All Zohar Keren's Colleagues
Zohar Keren's Contact Details
HQ
305-371-4112
Location
Israel
Company
Protalix Biotherapeutics
Zohar Keren's Company Details
Protalix Biotherapeutics logo, Protalix Biotherapeutics contact details

Protalix Biotherapeutics

Miami, FL, US • 250 - 499 Employees
BioTech/Drugs

Protalix (NYSE, TASE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human α–Galactosidase–A protein for the proposed treatment of Fabry disease; OPRX–106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has partnered with Chiesi Global Rare Diseases, both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

B2B Biotechnology Cleantech Food & Beverages Healthcare Pharmaceuticals Solar Power Wind Power BioTech/Drugs Commercial Physical Research
Details about Protalix Biotherapeutics
Frequently Asked Questions about Zohar Keren
Zohar Keren currently works for Protalix Biotherapeutics.
Zohar Keren's role at Protalix Biotherapeutics is Project Manager.
Zohar Keren's email address is ***@protalix.com. To view Zohar Keren's full email address, please signup to ConnectPlex.
Zohar Keren works in the Research industry.
Zohar Keren's colleagues at Protalix Biotherapeutics are Mirela Jakoel, Zehavit Glants, Dror Kaldes, Yair Kirshner, Sheli Levy, Kobi Marom, Omri Er-El and others.
Zohar Keren's phone number is 305-371-4112
See more information about Zohar Keren